Translate page

Perspectives from Professor Jorge Cortes, MD

MD Anderson Cancer Center
University of Texas, Houston, USA

  • Different aspects on treatment discontinuation including 2nd treatment discontinuation and QoL assessment
  • Presentation of a new tyrosine kinase inhibitor
  • Generics making it into practice
  • Predictive markers and their impact on patients outcome
  • Considerations for treatment discontinuation in clinical practice including AE management

Perspectives on QoL assessment in CML patients from Dr Fabio Efficace, PhD 

Fondazione GIMEMA, Rome, Italy

Northwestern University, Feinberg School of Medicine, Chicago, USA

  • Importance of QoL assessment in CML
  • Correlation between QoL and adherence to therapy
  • Update on QoL data from the ENEST trials
  • Overview of measuring instruments to assess QoL and the importance of patient-related QoL measures

 

 

Keynote presentations from the recipients of the 2016 iCMLf Prizes

At the 18th Annual John Goldman Conference on CML in Houston the iCMLf Directors awarded the Foundation’s 2016 prize medals. This was followed by keynote presentations from the three prize winners. You can view web streams of the keynote presentations here.

Collage 2016 Keynotes Prizes

 

  • 2016 Rowley Prize: Professor Nora Heisterkamp 
  • 2016 Goldman Prize: Professor Hagop Kantarjian
  • 2016 iCMLf Prize: Associate Professor Susan Branford
 

Interview with Dr Johan Richter: Euro-ski trial

Dr. Johan Richter 2You will also find a podcast interview with Dr Johan Richter on stopping tyrosine kinase inhibitors in a large cohort of European myeloid patients: Results of the euro-ski trial on the EHA Learning Center.

To access the video click here and log-in on the EHA Learning Center platform with your EHA login details or create a free account. 

 

 

 

 

 

Perspectives on CML in the emerging economic regions

VEP Garcia Gonzalez Perspectives on CML in the emerging economic regions
Interview with Pat Garcia-Gonzalez CEO of The MAX Foundation and recipient of the 2015 iCMLf ERSAP Prize

  • What has been achieved so far to increase global access to therapy and care to patients?
  • What are the biggest challenges still to be met in the emerging regions?
  • What role do public-private partnerships play to grant access to treatment? 
  • What is the vision for CML management in the emerging regions?



Perspectives from PD Dr. Susanne Saußele
Universitätsklinikum Mannheim, Germany

  • Key criteria for treatment discontinuation
  • The impact comorbidity has on TKI decision making
  • Additional chromosomal aberrations - considerations in clinical practice
  • Highlights of EHA